Apologies if this has been posted, I may have missed it. MST initiated coverage last November. Fairly comprehensive report for NEU (one can register here too).
https://www.mstaccess.com.au/research-notes/
Valuation
A risk-adjusted discounted cash flow (DCF) presents a valuation of $436m,implying a share price of $4.25. The risk adjustment is based on industry data that measures probability of success at the different development stages. Current global markets data have been used to estimate sales, potential milestone payments and royalties for trofinetide and NNZ-2591. The valuation is supported by comparison to ASX-listed biotech companies Opthea (OPT.AX) A$753m Paradigm (PAR.AX) $581m, that are developing
drugs at a similar stage.
Trading, page-4
-
- There are more pages in this discussion • 464 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.03 |
Change
0.700(4.29%) |
Mkt cap ! $2.176B | |||
| Open | High | Low | Value | Volume |
| $16.49 | $17.21 | $16.44 | $11.40M | 677.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4624 | $17.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.05 | 20000 | 1 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| NEU (ASX) Chart |